Reference Detail

Ref Type
PMID
Authors Kyriakos P. Papadopoulos, Anthony W. Tolcher, Amita Patnaik, Drew Warren Rasco, Glenda Chambers, Murali Beeram, Ronald Savage, Terence Hall, Brian E. Schwartz, Julia Kazakin, Patricia LoRusso; START Center for Cancer Care, San Antonio, TX; START, San Anto
Title Phase 1, first-in-human study of ARQ 087, an oral pan-Fibroblast Growth Factor Receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors.
Journal J Clin Oncol
Vol
Issue
Date
URL http://meetinglibrary.asco.org/content/149025-156
Abstract Text J Clin Oncol 33, 2015 (suppl; abstr 2545)

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FGFR2 fusion intrahepatic cholangiocarcinoma sensitive Derazantinib Phase I Actionable In a Phase I trial, Derazantinib (ARQ 087) treatment resulted in partial response in 2 and stable disease in 1 of the 5 intrahepatic cholangiocarcinoma patients harboring FGFR2 fusions, and progressive disease in 5 patients without FGFR aberrations (PMID: 28972963; NCT01752920). detail... 28972963
SRC amp non-small cell lung carcinoma sensitive Derazantinib Phase I Actionable In a Phase I trial, ARQ 087 treatment resulted in 25% tumor reduction and stable disease for 36 weeks in a squamous non-small cell lung carcinoma patient harboring SRC amplification (PMID: 28972963; NCT01752920). 28972963 detail...